Flotufolastat F 18 PET/CT for Prostate Cancer

(ECLIPSE Trial)

This trial explores a new method to detect prostate cancer that may persist or recur after certain treatments. It employs a special imaging technique called flotufolastat F 18 PET/CT, which combines structural images with signals from prostate cancer cells. The aim is to determine if this method can identify cancer more easily and efficiently than traditional methods. Men who have had prostate cancer and received treatments such as laser or cryotherapy in the past 6-36 months may be suitable candidates. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify if you need to stop taking your current medications. However, if you are taking investigational agents, you must stop them at least 42 days before the trial starts.

Research has shown that flotufolastat F 18, a special dye used in PET/CT scans, is generally safe for patients. Studies have found that it effectively helps doctors identify prostate cancer spots. While primarily used for prostate cancer, it can also appear in other types of cancer, non-cancerous conditions, and normal tissues. Few reports of serious side effects exist, making it a promising tool for detecting disease. However, like any medical procedure, some mild side effects might occur, but they are usually easy to manage.¹²³⁴⁵

Flotufolastat F 18 is unique because it uses a radioactive tracer specifically designed for PET/CT imaging to detect prostate cancer more accurately. Unlike standard imaging options, which may include MRI or CT scans alone, this treatment involves a PET/CT scan that provides a more detailed view, potentially identifying cancerous cells that other methods might miss. Researchers are excited about this treatment because it could lead to earlier and more precise detection of prostate cancer, allowing for more tailored and effective treatment plans for patients.

Research has shown that flotufolastat F 18 PET/CT, which participants in this trial will undergo, is promising for detecting prostate cancer that persists or returns after treatment. One study found it could reliably identify cancerous areas larger than 5 mm, aiding doctors in treatment decisions. Another study demonstrated that flotufolastat F 18 could detect cancer spread in many patients who had previously undergone surgery or radiation. These findings suggest that flotufolastat F 18 PET/CT could be an effective and less invasive method for identifying remaining or returning prostate cancer.¹⁶⁷⁸⁹